Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
When was updated. Last tweet is from September.
Sorry but I don't want Fed legalization right now. I want this company to acquire as many companies as they can, in a healthy financial manner. If they legalize next year, mdcl may be outbid by Philip Morris etc.
SAFE is more important in my opinion.
I have to add that the previous post is my opinion only, based on detail reading of conf call transcripts.
SNWV has placed 70 systes so far. In October, they placed 12. In November, they want to place 20, and in Dec, 25. They said repeatedly that they are ' very comfortable' with these numbers.
Of course, placement is one thing, revenue is another; but still, that's a great start.
They are confident they will break even by mid 2020.
Their Target goal is 100 million in the
third or fourth year, this being the first year. So little extrapolation tells you that by end of 2021, they could be doing 100 million in sales. If they really hit that Target, the price sales multiple should be 15/20 for this kind of growth. ISRG has PS of 15.
So bottom line, if it all goes well, and mgmt is quite excited that it will go really well, you are looking at 1.5-2 billion dollar company in 2 years.
Very weird trading. Sells off rapidly, thebn no trading for almost 5 min. Then tried to come back again. Then another 3 min stop.
Pothead Andy say something you pos
The results were just fine. Trend is up and taking hold. 58 or 65 placements, in the grand scheme of things, is not important. Codes are getting applied more.
There is nothing anyone can do about faster adoption. It just takes freaking time.
This is what happens when when freaking herd have one pov. In this case, it was that on Nov 1, Andy the magician wouldake MDCL the hottest stock in Colorado.
Until Medipharm gets absorbed, nothing will happen. And why did the guy promise about Medipharm merger way back when.
10 q out
Thanks. What is his email.
It is ok that Bitcoin is not moving higher right now. But if,when it crosses 13000, I want this ticket symbol to be ready. That will be a repeat of 2017, if Bitcoin crosses 13000. That will surely propel Bitcoin to all time high. For now it is churning, and that's ok. But o want Intellabridge to be ready.
What the hell is going on with this stock
Just that Andy is pissing me off to Grand promise and very little substance to show for. Hope he doesn't get high at work.
Unfortunately this jerk Williams will probably say that they are ' still working'on the acquisitions, and no company has merged yet
2.5 unfortunately
http://archive.fast-edgar.com//20191104/AIA2922CZC2232Z2222U2WZDA374HS22S2B2/
This is a direct purchase which is a good thing.
When it is Oman they are excited about look for this year guidance to disappoint. Maybe next year
Why is Schwab showing CUSID, and not allowing to trade. What is the new symbol for Intellabridge.
Thanks
US military defense is increasing. I have witnessed two microcap companies become multi billion dollar companies in mkt cap in as little as three years.
Both were companies that had A product the military really wanted. Just one product. When they want it, they will go out of their way, and their budget.
Ceradyne was a microcap before Iraq War. The military started buying their Kevlar vest, and in a few years it turned into almost billion dollar valuation.
Same thing with flir night vision camera.
Don't know how much USM likes echoscope. But if they like it as much as the other two, this is extremely cheap now.
Another positive when investing in defense stocks is that the downside will be much less when the market corrects.
This is the new FLIR. Check out flir in 2002. It had a 100 million market cap.
FLIR makes one product, night vision camera for defense. CODA makes one major prodct, the echoscope.
A request
I am a long time holder but first time poster. I would like to request stevenrisk and Ford to take a trip to Oregon and check out what the hell is happening with this company. I can contribute 500 bucks. I am sure others can too.
This has become a binary investment now.
Dr BJP Sinha
LMAO, BJP is the ruling party in India. Thay probably checked to see a genuine Indian name. So they google India news, see BJP everywhere, and there you have a name BJP Sinha.
There is one BKP Sinha though, in Forestry.
http://www.amity.edu/asnrsd/faculty.asp
If it is BKP Sinha, you can email him with DDCC's release.
Mine was deleted from a private server by a hack.
As long as crap king MJNA has 145 million mkt cap, and dilution king with shady mgmt including its CFO,TRTC has 140 mill mkt cap, and even a non-existent company PHOT has a 15 mill mkt cap and CBIS has mkt cap of 30 million, WE HAVE A LONG LONG WAY TO GO.
PESI --
The report focuses on "Nuclear Medicine Market and Radiopharmaceuticals [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha radiation therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & Stable Isotopes (Deuterium, C-13) - Global Trends & Forecast to 2017"
The market of radiopharmaceuticals is dominated by diagnostic radioisotopes, comprising of SPECT and PET radioisotopes. The lions share of the SPECT market is taken up by Tc-99m, whereas the PET market is dominated by F-18FDG isotope. Furthermore, the PET market will witness a double digit growth during the forecast period. The therapeutic segment contributes only 10% to the global radiopharmaceuticals market and I-131 has been considered as the gold standard for various oncology treatments in a combined therapy. Global nuclear medicines market is majorly driven by the increasing adoption of PET and SPECT scanners, and rising awareness for radiopharmaceuticals, whereas short half life of isotopes and stringent regulations are the factors that are hindering the growth of radiopharmaceuticals worldwide.
Browse Full Report @http://www.jsbmarketresearch.com...
Besides highly preferred isotopes such as Tc-99m and F-18, significant growth is witnessed for Tl-201 and Rb-82 in diagnostic market and Y-90 and Lu-177 in beta therapy radioisotopes market. Exhaustive pipeline analysis reveals that coronary heart disease, Alzheimers disease, breast cancer, and bone metastasis will drive the diagnostic radiopharmaceuticals market, whereas lymphoma, prostate cancer, bone metastasis, and hepatocellular carcinoma will boost the future of therapeutic radiopharmaceuticals. Besides new applications, the potential molecules that are expected to drive the market include Alpharadin (Ra-223), Ga-68, F-18 florbetapir, and F-18 choline. Though Ra-223 application is still under clinical trial, the market is highly optimistic regarding its clinical efficiency in prostate cancer, and bone metastasis.
North America held the largest share in the global radiopharmaceuticals market. The U.S. market is highly supported by the Mo-99 production of NRU reactor (Canada) and ongoing researches in different clinical institutes such as National Cancer Institute, Avid Radiopharmaceuticals and so on. Besides developed markets, the Asia-Pacific region is expected to show a remarkable growth in the coming years. China, India, Japan, South Korea, Brazil, and South Africa are expected to show a high growth potential amongst the emerging geographies. These countries are influenced by the domestic production of isotopes by reactors and government initiatives.
Apart from upcoming isotopes and their applications, understanding of the interlinked supply chain was imperative for market estimation. Value chain analysis and pipeline analysis have taken care of such business issues to come up with a consolidated market analysis, including the present and future impact of different factors. Demand and supply analysis identifies the potential risk of the interrupted supply of Mo-99 for the Tc-99m production, due to scheduled shutdown of major reactors and the benchmarking trend adopted by leading players to combat such operational difficulties.
The radiopharmaceutical market has been analyzed from both the radiopharmaceuticals processors and generator manufacturers perspectives. It has been identified that shifting from HEU to LEU is the major strategy in the processors market, while strengthening the supply chain of radiopharmaceuticals is the prime concern for the generator manufacturers.
In addition to the market size and forecast for radioisotopes, the report also covers competitive landscape and key developments of major players, pipeline analysis, investment opportunities, and regulatory affairs for established players as well as new entrants.
Custom Research/Customization details
RADIOPHARMACEUTICALS MARKET
1. PET and SPECT procedural volume (No. of procedures) at regional level and by Isotope
Estimation of diagnostic and therapeutic procedures in North America, Europe, Asia, and RoW for 2010, 2011, 2012, and the forecast for 2017
Estimation of SPECT, PET, Beta emitters and Brachytherapy procedures in North America, Europe, Asia, and RoW for 2010, 2011, 2012, and forecast for 2017
Radiopharmaceutical market for South Africa & Brazil
Market size estimation for South Africa and Brazil for 2010, 2011, 2012, and forecast for 2017
Regulatory affairs pertaining to Radiopharmaceutical market in South Africa and Brazil
2. Difference between carrier added and non carrier added Lu-177 molecule
Various advantages and disadvantages of carrier added and non carrier added Lu-177 molecule
3. Switzerland Radiopharmaceuticals Market
Market size estimation of diagnostic and therapeutic radioisotopes in Switzerland for 2010, 2011, 2012, and forecast for 2017
Market size estimation of SPECT and PET isotopes for 2010, 2011, 2012, and forecast for 2017
Market size estimation of Beta emitters and Brachytherapy isotopes for 2010, 2011, 2012, and forecast for 2017
Regulatory affairs pertaining to Radiopharmaceutical market in Switzerland
Market share analysis of Swiss Radiopharmaceutical market
For More Related Market Research Reports click here
Asthma Treatment Drugs Markets in China
Pain and Fever Relief Drugs Markets in China
how many outstanding shares are there in total, including diluted, preferred, everything.
sent mail to ir but never got answer back. makes me suspicious.
i think they are finally turning a corner here, don't you think.
also, what are the chances that they do 5 million in the coming quarters. I don't think there is any lumpiness to their quarters, since mPOS will only grow bigger.
if you have the ability to 'carl icahn' the company( i have no doubt that you do, since you may be THE most knowledgeable person wrt SCKT, and have accumulated lots of followers. In fact, can't you foment a small coup and oust Kevin. The guy doesn't deserve to be in silicon valley. He should be shipped to Mississippi el pronto.
thanks for your detailed report. a very rudimentary question: isn't socket scanner being used by brick and mortar stores when they are replacing their legacy cash registers with ipad and socket. there must be other scanners, but it is a given that this combination (ipad+scanner) will take over the traditional cash registers. where does shopkeep and shopify come into play.
i think the market knows this trend very well. it is just that it has been duped by socket for so long that it refuses to believe in the company. otherwise, the stockprice right now should sport a mc of 50 million dollars. having said that, 2 will be broken within a week, imo.
thanks again.
How is it looking this q. Looks like international is growing fast too.
Have the retailers started to convert en masse to mpos,
If so where does sckt fit. Thanks.
it is not a biotech stock. it is a medical device stock. biotechs fetch much higher premiums. having said that if edap gets fda approval, i have a feeling isrg or other big device manufacturers will buy it for no less than half billion bucks.
cannabidiol supplements are not easy to formulate. they are going after pharma-grade quality. the cbd supplements you see on amazon run for 60 dollars for 4 ounces. and who know where it comes from. read dp's terratech interview with benzinga about the current state of cbd.
i am very glad that mj is so focused on cbd supplements, because i think it will be the next fish oil.
great thanks.
with potential to heal lots of seizures, migraines, allergies, etc, many companies including the established ones will jump on the cbd bandwagon, especially because it is legal. so what will nrti do to make its products better than the rest.
can you ask him what is going to distinguish the formulation of cbd supplements, since they have created a new scientific ad board. there must be a reason for that.
Alan,
Shouldn't CIIX be in your 'legit' portfolio.
http://finance.yahoo.com/news/medicine-man-technologies-announces-first-140000557.html
CIIX had huge earnings and rev growth this past year. Based on reasonable estimates, they could have 20 cents earnings and 5 million revenue next year. That is WITHOUT medicine man and other cannabis related stocks. That itself equate to around $4 in stock price.
With a low float and os of around 5 million shares, this could blast upwards quickly, if and when it catches the cannabis momentum
Just think, a totally worthless hyped stock MDBX STILL has around 1 billion in market cap.
This is by far the cheapest stock in the cannabis sector. And Medicine Man wants to become Costco of Weeds.
http://news.yahoo.com/marijuana-costco-of-weed-170505979.html
CIIX LOW FLOAT 0.03 EPS LAST QUARTER, MEDICINE MAN FINANCIAL CONSULTING
http://finance.yahoo.com/news/chineseinvestors-com-otcbb-ciix-announces-133000344.html
1-million-signatures-for-florida-medical-marijuana-drive
http://mmjbusinessdaily.com/1-million-signatures-for-florida-medical-marijuana-drive/
if the management is reading this board,
DDCC should sell gold property at a great price, and once the share goes to 0.2, do a 1:10 reverse split, which would bring the share count to very attractive level.
Believe me, it is much easier for stock price to go from 2 to 10 as opposed to 0.2 to 1.
way more, like around 2 billion, if the product gets approved. Esai bought MGI Pharma in 2007, primarily for Aloxi, for around 4 billion.
APPA's drug delivery is more 'slow and steady' than that of Aloxi.